The startup develops non-nucleotidic small molecule inhibitors that target cancer and infectious diseases through a multimodal approach combining engineered viruses and small molecules. This method enhances immune system modulation, providing a novel therapeutic strategy for patients facing these health challenges.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Current cancer and infectious disease treatments often fail due to the limited ability to modulate the innate immune system effectively. Existing therapies may not fully harness the body's natural defenses, leading to suboptimal outcomes for patients.
Solution
Avammune Therapeutics is developing small molecule modulators of the innate immune system to treat cancer. Their approach integrates target biology, immunology, computational chemistry, and high-throughput chemistry to identify novel drug targets. This leads to a pipeline of best-in-class and first-in-class small-molecule drug candidates. These modulators enhance the body's ability to recognize and eliminate cancer cells by targeting key molecular pathways involved in immune regulation and tumor growth. Avammune's lead assets include ENPP1 and ADAR1 inhibitors, which have demonstrated promising preclinical results as monotherapies and in combination with existing cancer treatments.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking novel therapeutic approaches to modulate the innate immune system for cancer treatment.
Features
- AVA-NP-695: An orally available ENPP1 inhibitor approaching IND-enabling stage, shown to activate the STING pathway and reduce tumor metastasis in preclinical studies.
- AVA-NP-695 demonstrates enhanced mean survival time when combined with anti-PD-L1, Olaparib, and Paclitaxel.
- AVA-NP-695, in combination with radiation, resulted in complete tumor regression in animal models.
- AVA-ADR-001: A first-in-class small molecule inhibitor of ADAR1 that binds directly to the Zα domain of ADAR1 p150 isoform.
- AVA-ADR-001 demonstrates micromolar EC50 and anti-tumor efficacy in the B16F10 melanoma syngeneic mouse model.
- AVA-ADR-001 treatment resulted in 45% tumor growth inhibition (TGI), which is 1.5 times superior to Anti-PD1 treatment.
- Combination of AVA-ADR-001 with Anti-PD1 demonstrated a synergistic effect that was 2 times superior to Anti-PD1 alone.